[{"id":"bc8a1dac-21fa-40ef-8e4f-747e6a474e6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04458389","created_at":"2021-01-18T21:26:23.004Z","updated_at":"2024-07-02T16:36:26.371Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas","source_id_and_acronym":"NCT04458389","lead_sponsor":"Tayu Huaxia Biotech Medical Group Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TY 101"],"overall_status":"Recruiting","enrollment":" Enrollment 268","initiation":"Initiation: 12/07/2020","start_date":" 12/07/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2021-08-13"}]